Biogen reported strong Q3 2026 financial results, significantly beating analyst expectations for both adjusted EPS and revenue. The company also raised the lower end of its full-year 2026 non-GAAP EPS guidance, indicating improved financial performance and a positive outlook driven by newer drug assets.
Biogen announced Q3 2026 adjusted EPS of $2.62, significantly exceeding the FactSet consensus of $1.99, and revenue of $2.80 billion, also beating estimates. This strong performance is a positive signal for the company, especially as it navigates competitive pressures in its established multiple sclerosis franchise by focusing on newer drug assets. The decision to raise the low end of its fiscal year 2026 non-GAAP EPS guidance to $12.20-$13.00 further reinforces a positive short-term outlook. For traders, this suggests potential upward momentum for BIIB stock, as the company demonstrates effective strategy execution and financial outperformance, mitigating concerns about older drug portfolios.